NCT05238948View on ClinicalTrials.gov

CKD-506 Drug-Drug Interaction Study in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 28, 2022

Primary Completion Date

April 29, 2022

Study Completion Date

April 29, 2022

Conditions
Drug Drug Interaction
Interventions
DRUG

Midazolam

Substrate of CYP3A4

DRUG

CKD-506

Perpetrator of CYP3A4

Trial Locations (1)

9728

PRA Health Sciences, Groningen

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY